pharmaphorum
MAY 19, 2022
He was found guilty in 2017 of securities fraud schemes involving two hedge funds that he ran, sending fake account statements in order to conceal huge losses, and also convicted of manipulating the price and trading volume of stock in Retrophin, another pharma company he founded in 2011. In January, Shkreli was ordered to repay $64.6
Drug Patent Watch
JANUARY 7, 2025
The Importance of Generic Drugs in Healthcare Generic drugs offer several benefits to patients and the healthcare system: Cost-effectiveness: Generic drugs are typically much cheaper than brand-name medications, making treatment more accessible to patients. ” Health Affairs, 2011. ” WHO.int, 2020.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JANUARY 8, 2025
Filing too early might mean your patent expires before you’ve had a chance to fully commercialize your drug. The First-to-File System Since the America Invents Act of 2011, the U.S. Key Takeaways Optimizing your drug patent strategy is a complex but essential task for pharmaceutical companies.
European Pharmaceutical Review
SEPTEMBER 14, 2023
Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks. Ventola CL.
FDA Law Blog: Biosimilars
SEPTEMBER 15, 2024
The PREVAIL Act In short, the PREVAIL Act is intended to, among other things, reform the Inter Partes Review (“IPR”) process created by the 2011 Leahy-Smith America Invents Act. 2220, the Promoting and Respecting Economically Vital American Innovation Leadership Act (“ PREVAIL Act ”); and (2) S. beware of Roger “Verbal” Kint.
Pharmaceutical Technology
JANUARY 6, 2023
In the case of Novartis’ antihypertensive drug Exforge (amlodipine and valsartan), retail pharmacies including CVS, Walgreens, and two other plaintiff groups accused Novartis and Endo International’s Par Pharmaceutical unit of forming an illegal “reverse payment” agreement to delay the launch of less expensive generic versions of the drug.
Ramblings of a pharmacist
FEBRUARY 16, 2022
Digest per prescription revenue figure is believable (it’s also down about $6 since I started paying attention to the Digest , hence my annoyance at people that blame pharmacists for “skyrocketing drug prices.” In other words, the $55.96 prescription transaction.
Expert insights. Personalized for you.
21 
Let's personalize your content